Comparison of three real-time PCR assays for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in young pregnant women

Peuchant, Olivia; Diego, Soraya; Roy, Chloé Le; Frantz-Blancpain, Sandrine; Hocké, C.; Bebear, Cécile; Barbeyrac, Bertille de

doi:10.1016/j.diagmicrobio.2015.09.002

Cited by 11 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These tests generally fail to meet the high levels of sensitivity and specificity required for a POCT. The GeneXpert CT/NG Assay is the only commercial NAAT-based POCT for N. gonorrhoeae diagnosis and has high sensitivity (95.6–98%) and specificity (99.9–100%) which is dependent on the specimen type [ 13 , 30 , 31 , 32 , 33 ]. This assay requires 3 steps and takes 90 minutes to produce results [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of a Hydrogel-Based Diagnostic Approach for the Point-of-Care Based Detection of Neisseria gonorrhoeae

Perera

Taheri²,

Khan³

et al. 2018

Antibiotics

View full text Add to dashboard Cite

Eleven primer pairs were developed for the identification of Neisseria gonorrhoeae. The sensitivity and specificity of these primers were evaluated by Real Time (RT)-PCR melt curve analyses with DNA from 145 N. gonorrhoeae isolates and 40 other Neisseria or non-Neisseria species. Three primer pairs were further evaluated in a hydrogel-based RT-PCR detection platform, using DNA extracted from 50 N. gonorrhoeae cultures. We observed 100% sensitivity and specificity in the hydrogel assay, confirming its potential as a point-of-care test (POCT) for N. gonorrhoeae diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of a Hydrogel-Based Diagnostic Approach for the Point-of-Care Based Detection of Neisseria gonorrhoeae

Perera

Taheri²,

Khan³

et al. 2018

Antibiotics

View full text Add to dashboard Cite

show abstract

“…Women will be recruited in France in primary care from 4 free STI screening centers “CeGIDD” (“Centre Gratuit d’Information, de Dépistage et de Diagnostic”) and from 3 pregnancy termination centers after they had an abortion. We chose these centers because of the high prevalence of urogenital C. trachomatis infections (10 – 12%) [3,4,21] and because the French National Authority for Health recommends screening for vaginal C. trachomatis infection in these populations. [3,21]…”

Section: Methodsmentioning

confidence: 99%

Randomized, open-label, multicenter study of azithromycin compared with doxycycline for treating anorectal Chlamydia trachomatis infection concomitant to a vaginal infection (CHLAZIDOXY study)

Peuchant¹,

Lhomme

Krêt

et al. 2019

Medicine

Self Cite

View full text Add to dashboard Cite

Background: Chlamydia trachomatis can lead to a persistent infection in the lower gastrointestinal tract, suggesting a potential role of autoinoculation of cervical chlamydial infection from the rectal site, contributing to repeat infections. Moreover, around 75% of women with urogenital C. trachomatis have concurrent anorectal infection. Current treatment guidelines for urogenital C. trachomatis infection recommend either a single 1 g dose of azithromycin or doxycycline 100 mg twice daily for 7 days. Doxycycline appears to be more effective in treating anorectal infections as suggested in a population of men who have sex with men, but no randomized controlled trial (RCT) had directly compared azithromycin with doxycycline for the treatment of rectal infections. We propose an open-label RCT to compare the microbial cure obtained with a single 1 g dose of azithromycin versus 100 mg of doxycycline twice daily for 7 days, for the treatment of anorectal C. trachomatis infection concurrent to urogenital infection in women. Methods and study design: A total of 460 women with C. trachomatis urogenital infection will be enrolled in the study. Women will be asked to provide self-collected anorectal swabs and will be randomized to receive either a 1 g single dose of azithromycin or doxycycline 100 mg twice daily for 7 days. Clinical and biological data will be collected and patients will complete questionnaires about their sexual behavior. The primary outcome is the microbial cure rate, defined as a C. trachomatis negative nucleic acid amplification test (NAAT) result in the anorectal specimens 6 weeks after treatment initiation among women with a C. trachomatis positive urogenital and anorectal NAAT result at the baseline. The secondary outcome is autoinoculation from the rectum to the vagina, which will be evaluated based on the number of women with the same C. trachomatis genotype profile that will be identified in an anorectal-positive specimen obtained 6 weeks after treatment initiation and in a vaginal-positive specimen obtained four months after treatment. Discussion: The results of this trial will establish which treatment is more efficacious against anorectal infection and could affect recommendations for the treatment of urogenital C. trachomatis infection, taking into account concurrent anorectal infection. Trial registration numbers: EudraCT number: 2017-002595-15. ClinicalTrials.gov Identifier: NCT03532464. Date of registration: May 31, 2018. World Health Organisation International Clinical Trials Registry: NTC03532464. Secondary ID: CHUBX 2016/26. Date of registration: May 09, 2018.

show abstract

“…No explanation for the low sensitivity of Xpert for detection of C. trachomatis for vaginal swabs was identified, and the poor performance spanned across all three lots of test cartridges used. Other studies (22,23) reported sensitivity of 97 to 98% for detection of C. trachomatis from vaginal swabs using Xpert.…”

Section: Discussionmentioning

confidence: 99%

Use of Nucleic Acid Amplification Testing for Diagnosis of Extragenital Sexually Transmitted Infections

et al. 2017

View full text Add to dashboard Cite

Nucleic acid amplification testing (NAAT) is the preferred method to detect Chlamydia trachomatis and Neisseria gonorrhoeae, but no commercial tests are cleared by the U.S. Food and Drug Administration for use with extragenital swab samples. This study evaluated the performance of the Gen-Probe Aptima Combo2 assay (Aptima) and the Cepheid Xpert CT/NG assay (Xpert) to detect C. trachomatis and N. gonorrhoeae in rectal and pharyngeal samples from 224 men and 175 women reporting a history of anal receptive sexual intercourse. Discordant results between the NAATs were repeated using the assays APTIMA CT or APTIMA GC, which target alternate primers, as the confirmatory tests. C. trachomatis was detected from 59 rectal swabs and 8 pharyngeal samples, with 97.7% and 99.5% agreement between the two test systems, respectively. For C. trachomatis, Xpert was 95% sensitive (95% CI, 86 to 99%) and Aptima was 92% sensitive (95% CI, 81 to 97%) from rectal swabs, while both systems were 100% sensitive from pharyngeal samples. N. gonorrhoeae was detected from 30 rectal and 40 pharyngeal samples, with 99.5% and 97.5% agreement between the two test systems. The sensitivity of Xpert for N. gonorrhoeae from rectal swabs was 100% (95% CI, 88 to 100%) versus 93% (95% CI, 78 to 99%) for Aptima. From pharyngeal swab samples, Xpert was 98% sensitive (95% CI, 87 to 99.9%) versus 93% (95% CI, 80 to 98%) for Aptima. For C. trachomatis, neither system was Ͼ95% sensitive from the rectum, though both were Ͼ99.5% specific. For N. gonorrhoeae, Xpert had higher sensitivity than Aptima, but with more false positives from pharyngeal samples.

show abstract

Comparison of three real-time PCR assays for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in young pregnant women

Cited by 11 publications

References 14 publications

Evaluation of a Hydrogel-Based Diagnostic Approach for the Point-of-Care Based Detection of Neisseria gonorrhoeae

Evaluation of a Hydrogel-Based Diagnostic Approach for the Point-of-Care Based Detection of Neisseria gonorrhoeae

Randomized, open-label, multicenter study of azithromycin compared with doxycycline for treating anorectal Chlamydia trachomatis infection concomitant to a vaginal infection (CHLAZIDOXY study)

Use of Nucleic Acid Amplification Testing for Diagnosis of Extragenital Sexually Transmitted Infections

Contact Info

Product

Resources

About